P
Pieter H.M. De Mulder
Researcher at Radboud University Nijmegen Medical Centre
Publications - 40
Citations - 1942
Pieter H.M. De Mulder is an academic researcher from Radboud University Nijmegen Medical Centre. The author has contributed to research in topics: Renal cell carcinoma & Head and neck squamous-cell carcinoma. The author has an hindex of 19, co-authored 40 publications receiving 1853 citations. Previous affiliations of Pieter H.M. De Mulder include Radboud University Nijmegen.
Papers
More filters
Journal ArticleDOI
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
Susanne Krege,Jörg Beyer,Rainer Souchon,Peter Albers,Walter Albrecht,Ferran Algaba,Michael Bamberg,István Bodrogi,Carsten Bokemeyer,Eva Cavallin-Ståhl,Johannes Classen,C Clemm,Gabriella Cohn-Cedermark,Stéphane Culine,Gedske Daugaard,Pieter H.M. De Mulder,Maria De Santis,Maike de Wit,Ronald de Wit,H. G. Derigs,Klaus Peter Dieckmann,Annette Dieing,Jean Pierre Droz,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,Xavier Garcia del Muro,Thomas Gauler,Lajos Géczi,Arthur Gerl,Jose Ramon Germa-Lluch,Silke Gillessen,Jörg T. Hartmann,Michael Hartmann,Axel Heidenreich,Wolfgang Hoeltl,Alan Horwich,Robert Huddart,Michael Jewett,Johnathan Joffe,William G. Jones,László Kisbenedek,Olbjørn Klepp,S. Kliesch,Kai Uwe Koehrmann,Christian K. Kollmannsberger,Markus A. Kuczyk,Pilar Laguna,Oscar Leiva Galvis,Volker Loy,Malcolm David Mason,Graham M. Mead,Rolf Mueller,Craig R. Nichols,Nicola Nicolai,Tim Oliver,D. Ondruš,Gosse O N Oosterhof,Luis Paz Ares,Giorgio Pizzocaro,Jörg Pont,Tobias Pottek,Thomas Powles,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Jutta Scheiderbauer,Hans U. Schmelz,Heinz Schmidberger,Hans-Joachim Schmoll,Mark Schrader,Felix Sedlmayer,Niels E. Skakkebæk,Aslam Sohaib,Sergei Tjulandin,Padraig Warde,Stefan Weinknecht,Lothar Weissbach,Christian Wittekind,Eva Winter,Lori Wood,Hans von der Maase +82 more
TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.
Journal Article
Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting
Pieter H.M. De Mulder,Carolien Seynaeve,Jan B. Vermorken,Peter A. van Liessum,Snezana Mols-Jevdevic,Elizabeth Lane Allman,Paul Beranek,Jaap Verweij +7 more
TL;DR: The authors compared the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting.
Journal ArticleDOI
Immunotherapy for Renal Cell Carcinoma
TL;DR: With the enhanced knowledge of tumor-immunology, the identification of immunogenic tumor proteins, and antibodies recognizing tumor-associated antigens, new treatment strategies with increased specificity and fewer side effects are of interest.
Journal ArticleDOI
Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study
J.C. Oosterwijk-Wakka,Dorien M. Tiemessen,Ivar Bleumer,I. Jolanda M. de Vries,W. Jongmans,Gosse J. Adema,Frans M.J. Debruyne,Pieter H.M. De Mulder,Egbert Oosterwijk,Peter F.A. Mulders +9 more
TL;DR: The feasibility of a completely autologous DC and tissue culture methodology for the generation of TuLy pulsed DC is shown, suggesting that the vaccination strategy with immature DC has little benefit for patients with advanced RCC.
Journal ArticleDOI
Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
Carla M.L. van Herpen,Jeroen van der Laak,I. Jolanda M. de Vries,Johan H. J. M. van Krieken,Peter C.M. de Wilde,Michiel G.J. Balvers,Gosse J. Adema,Pieter H.M. De Mulder +7 more
TL;DR: Patients, irrespectively of IL-12 treatment, with a high number of CD56+ cells in the primary tumor had a better overall survival than those with a low number and a high IFN-γ mRNA expression in the lymph nodes.